MATCH-TRIAL-SCLC

Regimen

Experimental
Cisplatin/carboplatin + etoposide + atezolizumab 1200 mg + concurrent LDRT 15 Gy/5 fx (3 Gy/fx) x4 cycles, then atezolizumab maintenance
Control
None (single-arm)

Population

Treatment-naive extensive-stage SCLC, enrolled Dec 2020 - Mar 2022 across Chinese multicenter sites

Key finding

Confirmed ORR 87.5% (95% CI 75.9-94.8); mPFS 6.9 mo (95% CI 5.4-9.3); mOS 16.9 mo (95% CI 14.0-32.9); 3-yr OS 35.1%; deep responders (>70.2% depth) 3-yr OS 57.4% vs 18.8% (HR 0.28)

Source: PMID 40609842

Timeline

    Guideline citations

    • CSCO SCLC 2025 (p.68)⚠️ OCR source